NASDAQ:JNP - Columbia Laboratories Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.60 -0.10 (-1.15 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$8.70
Today's Range$8.35 - $8.75
52-Week Range$3.90 - $13.25
Volume35,500 shs
Average Volume93,553 shs
Market Capitalization$96.58 million
P/E Ratio-57.33
Dividend YieldN/A
Beta0.49

About Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories logoJuniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

Receive JNP News and Ratings via Email

Sign-up to receive the latest news and ratings for JNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNP
CUSIPN/A
Phone617-639-1500

Debt

Debt-to-Equity Ratio0.06
Current Ratio3.77
Quick Ratio3.15

Price-To-Earnings

Trailing P/E Ratio-57.33
Forward P/E Ratio57.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.98 million
Price / Sales1.91
Cash Flow$0.0173 per share
Price / Cash496.55
Book Value$3.83 per share
Price / Book2.25

Profitability

EPS (Most Recent Fiscal Year)($0.15)
Net Income$-2,060,000.00
Net Margins0.28%
Return on Equity1.49%
Return on Assets1.04%

Miscellaneous

Employees155
Outstanding Shares11,100,000

Columbia Laboratories (NASDAQ:JNP) Frequently Asked Questions

What is Columbia Laboratories' stock symbol?

Columbia Laboratories trades on the NASDAQ under the ticker symbol "JNP."

How were Columbia Laboratories' earnings last quarter?

Columbia Laboratories, Inc. (NASDAQ:JNP) released its quarterly earnings data on Thursday, May, 10th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.04. The specialty pharmaceutical company earned $15.52 million during the quarter, compared to the consensus estimate of $15.33 million. Columbia Laboratories had a return on equity of 1.49% and a net margin of 0.28%. View Columbia Laboratories' Earnings History.

What price target have analysts set for JNP?

3 equities research analysts have issued 1-year price targets for Columbia Laboratories' stock. Their predictions range from $24.00 to $34.00. On average, they anticipate Columbia Laboratories' stock price to reach $29.00 in the next twelve months. View Analyst Ratings for Columbia Laboratories.

Who are some of Columbia Laboratories' key competitors?

Who are Columbia Laboratories' key executives?

Columbia Laboratories' management team includes the folowing people:
  • Ms. Alicia Secor, Pres, CEO & Director (Age 55)
  • Dr. Nikin Patel Ph.D., MRPharmS, COO & Director (Age 45)
  • Mr. Jeffrey E. Young, CFO, Sr. VP of Fin., Treasurer & Sec. (Age 45)
  • Dr. Shen Luk BSc, Ph.D., Chief Scientific Officer
  • Dr. Claire Madden-Smith BSc, Ph.D., Sr. VP of Juniper Pharma Services

Has Columbia Laboratories been receiving favorable news coverage?

News stories about JNP stock have trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Columbia Laboratories earned a news impact score of 0.01 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 46.12 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Columbia Laboratories?

Shares of JNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Columbia Laboratories' stock price today?

One share of JNP stock can currently be purchased for approximately $8.60.

How big of a company is Columbia Laboratories?

Columbia Laboratories has a market capitalization of $96.58 million and generates $49.98 million in revenue each year. The specialty pharmaceutical company earns $-2,060,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Columbia Laboratories employs 155 workers across the globe.

How can I contact Columbia Laboratories?

Columbia Laboratories' mailing address is 33 Arch Street, Boston MA, 02110. The specialty pharmaceutical company can be reached via phone at 617-639-1500 or via email at [email protected]


MarketBeat Community Rating for Columbia Laboratories (JNP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about Columbia Laboratories and other stocks. Vote "Outperform" if you believe JNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Columbia Laboratories (NASDAQ:JNP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Columbia Laboratories in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 237.21%. The high price target for JNP is $34.00 and the low price target for JNP is $24.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$29.00$23.00$23.00
Price Target Upside: 237.21% upside211.83% upside374.23% upside389.36% upside

Columbia Laboratories (NASDAQ:JNP) Consensus Price Target History

Price Target History for Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories (NASDAQ:JNP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018Roth CapitalBoost Price TargetBuy$12.00 ➝ $24.00LowView Rating Details
11/6/2017HC WainwrightReiterated RatingNeutralN/AView Rating Details
7/14/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$31.00 ➝ $34.00LowView Rating Details
8/18/2016Northland SecuritiesDowngradeOutperform ➝ Market PerformN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Columbia Laboratories (NASDAQ:JNP) Earnings History and Estimates Chart

Earnings by Quarter for Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories (NASDAQ:JNP) Earnings Estimates

Current Year EPS Consensus Estimate: $0.15 EPS
Next Year EPS Consensus Estimate: $1.4 EPS

Columbia Laboratories (NASDAQ JNP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1$0.02$0.06$15.33 million$15.52 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.11)$0.1070$16.00 million$11.79 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.17)($0.08)$12.55 million$12.99 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.03)$11.84 million$13.96 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.09)($0.13)$11.27 million$11.25 millionViewListenView Earnings Details
3/7/2017Q4 2016$0.45$0.88$15.33 million$20.93 millionViewListenView Earnings Details
11/15/2016Q3 2016($0.15)$0.02$10.58 million$11.56 millionViewN/AView Earnings Details
8/4/2016Q216($0.08)($0.16)$9.49 million$11.89 millionViewN/AView Earnings Details
5/4/2016Q116($0.08)$0.03$9.13 million$12.10 millionViewN/AView Earnings Details
3/10/2016Q415($0.02)($0.19)$7.89 million$7.60 millionViewN/AView Earnings Details
11/10/2015Q315($0.05)$0.09$7.10 million$11.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.03)$8.35 million$10.20 millionViewN/AView Earnings Details
5/6/2015Q115$0.04$0.07$7.80 million$8.30 millionViewN/AView Earnings Details
3/18/2015Q414$0.07($0.05)$7.93 million$7.30 millionViewN/AView Earnings Details
10/28/2014Q314$0.12$0.34$9.74 million$11.50 millionViewN/AView Earnings Details
7/31/2014Q2$0.11$0.01$6.86 millionViewN/AView Earnings Details
4/29/2014Q1 2014($0.01)$7.25 millionViewN/AView Earnings Details
3/5/2014Q413$0.08$7.10 million$7.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.16$0.20$6.75 million$7.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.02$0.03$6.50 million$7.02 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.03$0.01$6.50 million$6.30 millionViewN/AView Earnings Details
3/14/2013Q4 2012$0.02$0.03$7.60 million$6.10 millionViewN/AView Earnings Details
11/8/2012Q3 2012$0.08$0.08ViewN/AView Earnings Details
8/8/2012Q2 2012$0.08$0.16ViewN/AView Earnings Details
5/4/2012Q1 2012($0.74)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.08)($0.10)ViewN/AView Earnings Details
11/3/2011Q3 2011$0.22ViewN/AView Earnings Details
8/4/2011Q2 2011$0.08$0.83ViewN/AView Earnings Details
5/5/2011Q1 2011$0.08$0.63ViewN/AView Earnings Details
3/10/2011Q4 2010($0.24)$0.40ViewN/AView Earnings Details
11/4/2010Q3 2010($0.48)$0.07ViewN/AView Earnings Details
8/5/2010Q2 2010($0.72)($0.61)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.72)($1.06)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.64)($0.70)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.64)($0.86)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.80)($0.77)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.56)($0.78)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.56)($0.51)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.80)($0.31)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.80)($0.66)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.66)ViewN/AView Earnings Details
3/11/2008Q4 2007($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Columbia Laboratories (NASDAQ:JNP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Columbia Laboratories (NASDAQ JNP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 45.51%
Insider Trading History for Columbia Laboratories (NASDAQ:JNP)
Insider Trading History for Columbia Laboratories (NASDAQ:JNP)

Columbia Laboratories (NASDAQ JNP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2017James A GeraghtyDirectorBuy2,000$4.82$9,640.0065,153View SEC Filing  
9/13/2016James A GeraghtyDirectorBuy2,000$5.97$11,940.0063,153View SEC Filing  
8/31/2016George ElstonCFOBuy1,000$5.50$5,500.001,000View SEC Filing  
8/26/2016C Ann MerrifieldDirectorBuy2,000$5.63$11,260.0015,193View SEC Filing  
8/25/2016Alicia SecorInsiderBuy5,000$5.75$28,750.005,000View SEC Filing  
8/23/2016James A GeraghtyDirectorBuy7,000$5.96$41,720.0058,216View SEC Filing  
12/4/2015C Ann MerrifieldDirectorBuy1,600$12.14$19,424.007,129View SEC Filing  
11/19/2015Nikin PatelCOOBuy5,000$11.82$59,100.00189,384View SEC Filing  
11/18/2015Frank Condella JrCEOBuy5,000$11.68$58,400.0079,720View SEC Filing  
8/14/2015C Ann MerrifieldDirectorBuy3,000$9.90$29,700.00View SEC Filing  
6/15/2015Frank M ArmstrongDirectorBuy1,255$7.95$9,977.25View SEC Filing  
6/9/2015Nikin PatelCOOBuy13,500$7.52$101,520.00View SEC Filing  
5/8/2015Frank Condella JrCEOBuy10,000$7.36$73,600.00View SEC Filing  
11/20/2014Donald H HunterDirectorBuy1,000$5.98$5,980.00View SEC Filing  
8/13/2014Frank Condella JrCEOBuy10,000$5.98$59,800.00View SEC Filing  
5/5/2014Frank Condella JrCEOBuy10,000$6.65$66,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Columbia Laboratories (NASDAQ JNP) News Headlines

Source:
DateHeadline
Edited Transcript of JNP earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of JNP earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 12 at 8:43 AM
Juniper Pharmaceuticals Inc (NASDAQ:JNP): Can It Deliver A Superior ROE To The Industry?Juniper Pharmaceuticals Inc (NASDAQ:JNP): Can It Deliver A Superior ROE To The Industry?
finance.yahoo.com - May 12 at 8:43 AM
Columbia Laboratories (JNP) Releases Quarterly  Earnings ResultsColumbia Laboratories (JNP) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 12:28 AM
Columbia Laboratories (JNP) Stock Rating Upgraded by ValuEngineColumbia Laboratories (JNP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
Juniper Pharmaceuticals: 1Q Earnings SnapshotJuniper Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:34 AM
Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating ResultsJuniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 10 at 8:34 AM
Columbia Laboratories (JNP) Rating Lowered to C at TheStreetColumbia Laboratories (JNP) Rating Lowered to C at TheStreet
www.americanbankingnews.com - May 3 at 9:55 PM
Columbia Laboratories (JNP) Upgraded at ValuEngineColumbia Laboratories (JNP) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 1:30 PM
Juniper Pharmaceuticals Inc (NASDAQ:JNP): Time For A Financial Health CheckJuniper Pharmaceuticals Inc (NASDAQ:JNP): Time For A Financial Health Check
finance.yahoo.com - May 3 at 8:32 AM
Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018
finance.yahoo.com - May 1 at 8:07 AM
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré BioscienceJuniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
finance.yahoo.com - April 25 at 8:39 AM
Columbia Laboratories (JNP) Downgraded by ValuEngineColumbia Laboratories (JNP) Downgraded by ValuEngine
www.americanbankingnews.com - April 23 at 11:18 PM
Columbia Laboratories (JNP) Upgraded to "Buy" by ValuEngineColumbia Laboratories (JNP) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 8 at 11:48 AM
Juniper Pharmaceuticals (JNP) Upgraded by ValuEngine to HoldJuniper Pharmaceuticals (JNP) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 3 at 11:08 AM
Juniper Pharmaceuticals (JNP) Rating Reiterated by HC WainwrightJuniper Pharmaceuticals (JNP) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 1 at 7:35 PM
Where Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) Earnings Growth Stands Against Its IndustryWhere Juniper Pharmaceuticals Inc’s (NASDAQ:JNP) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 28 at 5:19 PM
Juniper Pharmaceuticals (JNP) Downgraded by ValuEngineJuniper Pharmaceuticals (JNP) Downgraded by ValuEngine
www.americanbankingnews.com - March 28 at 11:55 AM
Juniper Pharma (JNP) Names Richard Messina to Board - StreetInsider.comJuniper Pharma (JNP) Names Richard Messina to Board - StreetInsider.com
www.streetinsider.com - March 23 at 8:22 AM
Juniper Pharmaceuticals Appoints Richard Messina to Board of ... - PR Newswire (press release)Juniper Pharmaceuticals Appoints Richard Messina to Board of ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:27 AM
Juniper Pharmaceuticals Appoints Richard Messina to Board of DirectorsJuniper Pharmaceuticals Appoints Richard Messina to Board of Directors
finance.yahoo.com - March 21 at 5:37 PM
At $12, Is Juniper Pharmaceuticals Inc (NASDAQ:JNP) A Buy?At $12, Is Juniper Pharmaceuticals Inc (NASDAQ:JNP) A Buy?
finance.yahoo.com - March 20 at 5:33 PM
Edited Transcript of JNP earnings conference call or presentation 8-Mar-18 1:30pm GMTEdited Transcript of JNP earnings conference call or presentation 8-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:54 AM
Analyzing Theravance Biopharma (TBPH) & Juniper Pharmaceuticals (JNP)Analyzing Theravance Biopharma (TBPH) & Juniper Pharmaceuticals (JNP)
www.americanbankingnews.com - March 16 at 7:50 AM
Juniper Pharmaceuticals (JNP) Upgraded at ValuEngineJuniper Pharmaceuticals (JNP) Upgraded at ValuEngine
www.americanbankingnews.com - March 16 at 12:16 AM
Juniper Pharmaceuticals (JNP) Upgraded to B- by TheStreetJuniper Pharmaceuticals (JNP) Upgraded to B- by TheStreet
www.americanbankingnews.com - March 14 at 7:20 AM
Comparing BioLife Solutions (BLFS) and Juniper Pharmaceuticals (JNP)Comparing BioLife Solutions (BLFS) and Juniper Pharmaceuticals (JNP)
www.americanbankingnews.com - March 13 at 11:54 AM
Juniper Pharmaceuticals (JNP) Upgraded to "Hold" by ValuEngineJuniper Pharmaceuticals (JNP) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 10 at 7:42 PM
Juniper Pharmaceuticals (JNP) Price Target Raised to $24.00Juniper Pharmaceuticals (JNP) Price Target Raised to $24.00
www.americanbankingnews.com - March 9 at 8:32 PM
Juniper Pharmaceuticals (JNP) Announces  Earnings Results, Beats Estimates By $0.22 EPSJuniper Pharmaceuticals (JNP) Announces Earnings Results, Beats Estimates By $0.22 EPS
www.americanbankingnews.com - March 9 at 4:15 PM
Juniper Pharmaceuticals, Inc. to Host Earnings CallJuniper Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 9:34 AM
Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating ResultsJuniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results
finance.yahoo.com - March 8 at 9:34 AM
Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2017 Results on March 8, 2018
finance.yahoo.com - March 2 at 8:45 AM
Juniper Pharmaceuticals (JNP) & Histogenics (HSGX) Financial ComparisonJuniper Pharmaceuticals (JNP) & Histogenics (HSGX) Financial Comparison
www.americanbankingnews.com - March 2 at 1:16 AM
 Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Announce Quarterly Sales of $13.20 Million Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Announce Quarterly Sales of $13.20 Million
www.americanbankingnews.com - February 19 at 2:22 AM
 Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Post Earnings of -$0.16 Per Share Brokerages Expect Juniper Pharmaceuticals Inc (JNP) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 17 at 11:16 PM
Juniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.16 Per ShareJuniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 1 at 1:12 AM
Juniper Pharma (JNP) to Explore Strategic AlternativesJuniper Pharma (JNP) to Explore Strategic Alternatives
www.streetinsider.com - January 31 at 3:28 PM
Juniper Pharmaceuticals to Explore Strategic AlternativesJuniper Pharmaceuticals to Explore Strategic Alternatives
finance.yahoo.com - January 31 at 3:28 PM
$13.20 Million in Sales Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter$13.20 Million in Sales Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter
www.americanbankingnews.com - January 17 at 10:08 PM
-$0.16 EPS Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter-$0.16 EPS Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter
www.americanbankingnews.com - January 15 at 1:08 AM
Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, GermanyJuniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany
finance.yahoo.com - January 8 at 9:25 AM
BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio ProgressBRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
www.businessinsider.com - January 3 at 3:35 PM
Juniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio ProgressJuniper Pharmaceuticals Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress
finance.yahoo.com - January 2 at 8:51 PM
Juniper Pharmaceuticals (JNP) Coverage Initiated by Analysts at Roth CapitalJuniper Pharmaceuticals (JNP) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - January 2 at 10:18 AM
Neuralstem (CUR) versus Juniper Pharmaceuticals (JNP) Critical ReviewNeuralstem (CUR) versus Juniper Pharmaceuticals (JNP) Critical Review
www.americanbankingnews.com - January 2 at 1:08 AM
Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?Juniper Pharmaceuticals Inc (NASDAQ:JNP): What’s The Analyst Consensus Outlook?
finance.yahoo.com - December 21 at 11:32 AM
ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 19, 2017ETFs with exposure to Juniper Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 3:35 PM
Juniper Pharmaceuticals Inc (JNP) Receives Average Recommendation of "Hold" from BrokeragesJuniper Pharmaceuticals Inc (JNP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 16 at 4:48 AM
Reviewing Juniper Pharmaceuticals (JNP) and Corium International (CORI)Reviewing Juniper Pharmaceuticals (JNP) and Corium International (CORI)
www.americanbankingnews.com - December 11 at 3:34 PM
Juniper Pharmaceuticals (JNP) Lowered to "Sell" at ValuEngineJuniper Pharmaceuticals (JNP) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 10:34 AM

SEC Filings

Columbia Laboratories (NASDAQ:JNP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Columbia Laboratories (NASDAQ:JNP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Columbia Laboratories (NASDAQ JNP) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.